Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Dr. Joseph DeSanto and BioCorRx Recovery Program Participant Appear on the TV Show, The Doctors

Posted on: 15 Feb 18

ANAHEIM, CA, Feb. 15, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that Dr. Joseph DeSanto, founder of the DeSanto Clinics and provider of the Company’s BioCorRx® Recovery Program, appeared on the nationally syndicated daytime talk show, The Doctors. Dr. DeSanto is a Board Certified MD with over 12 years of addiction treatment experience. The episode focuses on the journey of Dr. DeSanto’s patient, Anna, who was treated in his clinic using the BioCorRx® Recovery Program, which includes the use of a naltrexone implant and the Company’s proprietary cognitive behavioral therapy (CBT) program with accompanying peer support. Clips from the episode are available here

Brady Granier, CEO of BioCorRx, Inc., stated, “We are very proud of Anna. It’s takes extreme courage to seek help and then get on a national stage to talk about it. Hopefully her bravery will encourage others to find help. Although it wasn’t mentioned by name during the show, Anna participated in a protocol that we call B2NTX, which can be found on our website at That protocol includes the use of our BioCorRx® Recovery Program which Dr. DeSanto uses frequently in his practice.” 

About BioCorRx

BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit 

Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.

CONTACT: BioCorRx Inc. 714-462-4880 Investor Relations: Crescendo Communications, LLC (212) 671-1020 x304 bicx@crescendo-irGlobeNewswire

Last updated on: 15/02/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.